Miriam Kimel1, Nancy Kline Leidy1, Elizabeth Tschosik2, Chantal Dolan3, Eric H Souied4, Rohit Varma5, Neil M Bressler6. 1. Evidera, Bethesda, Maryland, United States. 2. Genentech, Inc., South San Francisco, California, United States. 3. CMD Consulting, Inc., Sandy, Utah, United States. 4. Centre Hospitalier Intercommunal, Créteil, France. 5. USC Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, United States. 6. Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Abstract
Purpose: To develop and validate the Functional Reading Independence (FRI) Index, a new patient-reported outcome measure assessing reading activities in individuals with geographic atrophy (GA) due to age-related macular degeneration. Methods: The Index was developed through expert consultation and qualitative patient interviews. Reliability, validity, and responsiveness were tested with data from the Mahalo study (NCT01229215) of lampalizumab in patients with GA. Results: Qualitative interviews (n = 40) yielded a 10-item FRI Index, which was refined to seven items in quantitative testing (n = 100). Strong internal consistency (marginal reliability = 0.90) and reproducibility (intraclass correlation coefficient = 0.86) were shown. Known-group validity testing for baseline mean FRI Index scores showed differences (mean [SD]) between patients with Minnesota Low-Vision Reading test reading speed ≥80 vs. <80 words per minute (3.0 [0.7] vs. 1.9 [0.7]; P < 0.001), and between patients above vs. below median values on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) score (2.9 [0.7] vs. 2.1 [0.8]; P < 0.001). Convergent validity with binocular measures was strong (Spearman's correlation = 0.72 for reading speed, 0.66 for NEI-VFQ-25). Analysis of sensitivity to change revealed mean FRI Index score changes for patients with GA lesion size growth ≥2.5 mm2/18 months of -0.41 (0.70) vs. -0.13 (0.61) for patients with lesion growth <2.5 mm2/18 months (P = 0.07). Conclusions: The FRI Index demonstrated good reliability and validity in patients with GA. Further study in a broader GA population is warranted to confirm responsiveness.
RCT Entities:
Purpose: To develop and validate the Functional Reading Independence (FRI) Index, a new patient-reported outcome measure assessing reading activities in individuals with geographic atrophy (GA) due to age-related macular degeneration. Methods: The Index was developed through expert consultation and qualitative patient interviews. Reliability, validity, and responsiveness were tested with data from the Mahalo study (NCT01229215) of lampalizumab in patients with GA. Results: Qualitative interviews (n = 40) yielded a 10-item FRI Index, which was refined to seven items in quantitative testing (n = 100). Strong internal consistency (marginal reliability = 0.90) and reproducibility (intraclass correlation coefficient = 0.86) were shown. Known-group validity testing for baseline mean FRI Index scores showed differences (mean [SD]) between patients with Minnesota Low-Vision Reading test reading speed ≥80 vs. <80 words per minute (3.0 [0.7] vs. 1.9 [0.7]; P < 0.001), and between patients above vs. below median values on the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) score (2.9 [0.7] vs. 2.1 [0.8]; P < 0.001). Convergent validity with binocular measures was strong (Spearman's correlation = 0.72 for reading speed, 0.66 for NEI-VFQ-25). Analysis of sensitivity to change revealed mean FRI Index score changes for patients with GA lesion size growth ≥2.5 mm2/18 months of -0.41 (0.70) vs. -0.13 (0.61) for patients with lesion growth <2.5 mm2/18 months (P = 0.07). Conclusions: The FRI Index demonstrated good reliability and validity in patients with GA. Further study in a broader GA population is warranted to confirm responsiveness.
Authors: Aneesha Ahluwalia; Liangbo L Shen; Yihan Bao; Mengyuan Sun; Benjamin K Young; Michael M Park; Lucian V Del Priore Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-10-21 Impact factor: 3.535
Authors: Evelyn P Semenov; Rebecca Sheplock; Alejandro J Roman; David B McGuigan; Malgorzata Swider; Artur V Cideciyan; Samuel G Jacobson Journal: Transl Vis Sci Technol Date: 2020-12-08 Impact factor: 3.283
Authors: Susanne G Pondorfer; Jan H Terheyden; Helen Overhoff; Jana Stasch-Bouws; Frank G Holz; Robert P Finger Journal: Transl Vis Sci Technol Date: 2021-01-06 Impact factor: 3.283
Authors: Sujata P Sarda; Anne Heyes; Meryem Bektas; Tanvee Thakur; Wendy Chao; Michele Intorcia; Samantha Wronski; Daniel L Jones Journal: Clin Ophthalmol Date: 2021-12-08